Flourish Research Secures Major Investment for Growth
Flourish Research, recognized as a notable force in the multi-site clinical trial field, has recently made headlines by securing a significant majority investment from Genstar Capital. This strategic partnership aims to strengthen Flourish’s leadership in the clinical trial sector, providing the necessary resources for further expansion across various therapeutic areas and regions.
Enhancing Clinical Trials Through Strategic Investment
With a solid operational foundation, Flourish Research is well-equipped to elevate how clinical trials are conducted. The company boasts an extensive network of 24 sites and more than 150 experienced investigators, concentrating on key areas such as cardiovascular health, metabolism, neuroscience, and infectious diseases. This new investment will increase its ability to provide timely and effective study results, which is vital in today’s fast-evolving medical environment.
Commitment to Diversity and Expertise
Reinhold Schulz, the Chief Executive Officer of Flourish Research, highlights the company’s exceptional capabilities. "Our network is rich in scientific and medical expertise, which enables us to improve both patient recruitment diversity and operational efficiency," Schulz noted. Flourish’s dedication to leveraging top-tier data analytics and technology further boosts its research effectiveness.
Genstar Capital’s Role in Flourish’s Journey
Genstar Capital, recognized for its strategic investments in healthcare and other dynamic industries, will be pivotal in Flourish’s growth journey. Scott Niehaus, a Director at Genstar, shared his excitement about their partnership, emphasizing Flourish's ability to tackle critical challenges in conducting successful clinical trials. He expressed admiration for Flourish’s growth and forward-thinking leadership.
Investment Philosophy and Collaborations
This collaboration is not just about fostering organic growth; it also opens up possibilities for potential acquisitions, further solidifying the company's position in the market. Luis Gonzalez from NMS Capital, who has been instrumental in helping Flourish build a fully integrated trial organization, believes this investment marks a defining moment in the company's quest for excellence.
Integrative Support for Accelerated Growth
The alliance with Genstar is set to bolster Flourish Research's strategic initiatives and infrastructure. Flourish has gained recognition for integrating diverse clinical trial sites, which streamlines processes for sponsors and Contract Research Organizations (CROs). This model significantly boosts the efficiency and speed of clinical research across multiple therapeutic fields.
Focus Areas and Future Directions
Flourish’s operations currently span several states, highlighting its commitment to a broad and inclusive clinical trial approach. Moving forward, this strategic investment offers unprecedented chances to enhance patient recruitment and retention efforts among diverse populations.
Acknowledgments and Expert Counsel
In this investment transaction, Jefferies LLC acted as the lead financial advisor, while Flourish received legal counsel from McDermott Will & Emery. The input of Cantor Fitzgerald & Co. and Houlihan Lokey played a significant role as well, providing a strong advisory framework throughout the investment process.
About Flourish Research
Founded to address the fragmented clinical trial site market, Flourish Research operates on a business model centered on acquiring and integrating high-quality sites. This unique approach allows Flourish to deliver swift and effective services across various therapeutic areas. With a firm commitment to advancing healthcare, Flourish continues to innovate how clinical research is conducted.
About NMS Capital and Genstar Capital
NMS Capital is a prominent private equity firm that has invested substantially in expanding companies since its inception in 2010. Managing over $1.5 billion in assets, NMS provides the operational resources necessary to enhance its portfolio's potential. Meanwhile, Genstar Capital has an extensive investment background spanning more than three decades, focusing on cultivating quality businesses in targeted sectors, including healthcare.
Frequently Asked Questions
What is Flourish Research known for?
Flourish Research specializes in conducting multi-site clinical trials across a variety of therapeutic areas, ensuring both quality and efficiency in its operations.
Who is Genstar Capital?
Genstar Capital is a private equity firm that invests in selective segments of healthcare and other industries, aiming to transform companies into market leaders.
How does the investment from Genstar affect Flourish Research?
The investment from Genstar paves the way for Flourish Research to expand its operations and improve patient recruitment efforts at its clinical trial sites.
What expertise does Flourish provide in clinical trials?
Flourish brings a wealth of scientific and medical expertise, along with industry-leading data analytics, and is committed to enhancing patient diversity in clinical research.
What are Flourish Research's future plans?
Flourish plans to utilize this investment to scale its operations, improve patient recruitment strategies, and potentially seek acquisition opportunities in the clinical trial market.
